Enlivex Therapeutics

#Immunology #Osteoarthritis #Sepsis #Macrophage Biology

Enlivex Therapeutics is a clinical-stage macrophage-reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore immune homeostasis in life-threatening inflammatory conditions and knee osteoarthritis.

Company Info

Sector:Immunotherapy & Cell Therapy

Headquarters:Ness Ziona, Israel

Founded:2005

Website:www.enlivex.com/

Clinical Development Pipeline

Allocetra

Target: Macrophage Reprogramming

Knee Osteoarthritis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Allocetra

Target: Macrophage Reprogramming

Sepsis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Workforce & Restructuring Tracker

View Industry Layoff Tracker →

2026-10-19•Pipeline Pivot & Reprioritization•Nes-Ziona, Israel

60% of workforceConfirmed

Macrophage-reprogramming cell therapy developer Enlivex laid off 60% of its workforce and implemented substantial executive salary reductions to extend cash runway around its Allocetra clinical programs.

Recent News

No recent news updates available for this company.

Leadership Team

Dr. Oren Hershkovitz

Chief Executive Officer

Shai Novik

Executive Chairman

Careers & Job Openings

No active job listings. Check back later.